Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Five Under 5: Top Oncology Videos for the Week of 2/16
Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age
Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
2 Commerce Drive
Cranbury, NJ 08512